Company / Current Liabilities
RAPT Therapeutics, Inc. Current Liabilities History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$48.4M
FY2024
5-year range
$9.6M / $48.4M
FY2020-FY2024
Trend
+121.4%
vs FY2023
Sector context
#144 of 214
Health Care
What the data says
At $48M, RAPT Therapeutics, Inc.'s current liabilities ranks #71 of 214 in the Health Care sector. Current Liabilities has increased for 3 consecutive years, from $10M in FY2021 to $48M in FY2024.
Based on SEC 10-K filings.
$48M in FY2024 with a 5-year CAGR of +39.2%.
Increased from $14M to $48M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +71.4%
- 5-Year CAGR
- +39.2%
- 10-Year CAGR
- -
Sector benchmark
#71 of 214 in Health CareTop 33% of 214This company $48.4M Sector average $1.6B
▼
-96.9% below sector average
Key checks
Key Insights
- RAPT Therapeutics, Inc.'s current liabilities has grown for 3 consecutive years.
- 5-year CAGR of +39.2%, indicating consistent growth.
- In FY2024, current liabilities increased 121.4% year-over-year.
- Ranks #144 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $48.4M | +121.4% |
| FY2023 | $21.8M | +53.5% |
| FY2022 | $14.2M | +48.2% |
| FY2021 | $9.6M | -18.3% |
| FY2020 | $11.7M | +26.9% |
| FY2019 | $9.3M | +99.4% |
| FY2018 | $4.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026